Calgary’s Ocumetics, a pioneer in vision enhancement technology, is excited to announce the successful development of a new injector system specifically designed for implantation of the Ocumetics Accommodative Intraocular lens.
This achievement marks a significant milestone in Ocumetics’ journey toward its first-in-human study scheduled for early 2025.
The new injector, meticulously crafted by Medicil, a renowned Swiss IOL (intraocular lens) injector manufacturer, is tailored to the unique specifications of the Ocumetics Lens, ensuring precise and efficient implantation.
This development is crucial for optimizing the surgical procedure, performance, and patient outcomes of this innovative lens, which is designed to provide optimal visual performance at all distances and improved quality of life for individuals with visually significant cataracts.
“We are delighted to have completed the development of this specialized injector in collaboration with Medicil,” said Dean Burns, CEO of Ocumetics.
“Their expertise and commitment to quality have been instrumental in achieving this milestone. This advancement brings us one step closer to our goal of revolutionizing vision correction after cataract surgery with the Ocumetics Accommodative IOL.”
The development of the Ocumetics Lens injector is a pivotal step in preparation for the upcoming first-in-human study.
This study, scheduled for early next year, is designed to evaluate the safety and efficacy of the Ocumetics Accommodative IOL in a clinical setting, providing crucial data to support future regulatory applications and commercialization.
Leave a Reply